Safety and immunogenicity of recombinant human thrombin: A pooled analysis of results from 10 clinical trials

Pharmacotherapy

Volumn 32, Issue 11, 2012, Pages 998-1005

  Singla, Neil K ^a   Foster, Kevin N ^b   Alexander, W Allan ^c   Pribble, John P ^c  

^a Lotus Clinical Research   (United States)

^b MARICOPA MEDICAL CENTER   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Antibody formation; Hemostatics; Recombinant protein; RThrombin; Surgery

Indexed keywords

PLACEBO; RECOMBINANT THROMBIN;

ANEMIA; ANTIBODY TITER; ARTERIOVENOUS SHUNT; ARTERY BYPASS; ARTICLE; BLOOD SAMPLING; CAUSE OF DEATH; CONSTIPATION; DEBRIDEMENT; DEEP VEIN THROMBOSIS; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; HEART ARREST; HEMODIALYSIS; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOTENSION; IMMUNOGENICITY; INCISION SITE PAIN; INSOMNIA; LIVER FAILURE; LIVER RESECTION; LUNG EMBOLISM; MONITORING; MONOTHERAPY; NAUSEA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); POSTOPERATIVE PAIN; PROCEDURAL PAIN; PRURITUS; RESPIRATORY FAILURE; SEPSIS; SKIN GRAFT; SPINE SURGERY; SUDDEN DEATH; SURGICAL TECHNIQUE; TREATMENT INDICATION; VASCULAR GRAFT THROMBOSIS; VOMITING;

ADULT; CHILD; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; FEMALE; HEMOSTATICS; HUMANS; INCIDENCE; MALE; POSTOPERATIVE HEMORRHAGE; RECOMBINANT PROTEINS; THROMBIN; UNITED STATES;

EID: 84871545921     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1128     Document Type: Article

References (19)

1. ZymoGenetics, a Bristol-Myers Squibb Company. Prescribing information: RECOTHROM®. Seattle, WA; 2009
2. King Pharmaceuticals, a Pfizer Company. Prescribing information: Thrombin-JMI®. Bristol, TN; 2011
3. Ethicon, Inc., a J & J Company. Prescribing information: EVITHROM ®. Somerville, NJ; 2010
4. Koren E, Zuckerman LA, Mire-Sluis AR. Immune responses to therapeutic proteins in humans - clinical significance, assessment and prediction. Curr Pharm Biotechnol 2002;3:349-60 (Pubitemid 35364009)
5. Schellekens H, Casadevall N. Immunogenicity of recombinant human proteins: causes and consequences. J Neurol 2004;251 (suppl 2):II4-9
6. Terrab A, Pawlak D, Spaay P, Hoppensteadt D, Fareed J. Further removal of factor V related antigen from bovine thrombin by utilizing a membrane-filtration step. Clin Appl Thromb Hemost 2008;14:135-40 (Pubitemid 351364022)
7. Paterson CA, Pixton GC, Proskin HM, et al. Immune responses associated with perioperative exposure and reexposure to topical bovine thrombin do not impair hemostasis. Clin Appl Thromb Hemost 2011;17:620-32
8. Doria C, Fischer CP, Wood CG, Li PM, Marra S, Hart J Phase 3, randomized, double-blind study of plasma-derived human thrombin versus bovine thrombin in achieving hemostasis in patients undergoing surgery. Curr Med Res Opin 2008;24:785-94 (Pubitemid 351428990)
9. Meehan WP, Bolton MG. Recombinant human thrombin: demonstration of efficacy in models of surgical bleeding [abstract P54]. J Surg Res 2004;121:323
10. Chapman WC, Lockstadt H, Singla N, Kafie FE, Lawson JH Phase 2, randomized, double-blind, placebo controlled, mulitcenter clinical evaluation of recombinant human thrombin in multiple surgical indications. J Thromb Haemost 2006;4:2083-5 (Pubitemid 44226801)
11. Greenhalgh DG, Gamelli RL, Collins J, et al. Recombinant thrombin: safety and immunogenicity in burn wound excision and grafting. J Burn Care Res 2009;30:371-9
12. Chapman WC, Singla N, Genyk Y, et al. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. J Am Coll Surg 2007;205:256-65 (Pubitemid 47095423)
13. Singla NK, Ballard JL, Moneta G, Randleman CD Jr, Renkens KL, Alexander WA. A phase 3b, open-label, single-group immunogenicity and safety study of topical recombinant thrombin in surgical hemostasis. J Am Coll Surg 2009;209: 68-74
14. Foster KN, Mullins RF, Greenhalgh DG, et al. Recombinant human thrombin: safety and immunogenicity in pediatric burn wound excision. J Pediatr Surg 2011;46:1992-9
15. Singla NK, Gasparis AP, Ballard JL, et al. Immunogenicity and safety of re-exposure to recombinant human thrombin in surgical hemostasis: a phase 4 Study. J Am Coll Surg 2011;213:722-7
16. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. March 31, 2003 (http://ctep.cancer.gov), Publish Date: August 9, 2006. Available from http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/docs/ ctcaev3.pdf Accessed September 6, 2012
17. Clopper C, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934;26:404-13
18. Elkon K, Casali P. Nature and functions of autoantibodies Nat Clin Pract Rheumatol 2008;4:491-8
19. Lutz HU, Binder CJ, Kaveri S. Naturally occurring autoantibodies in homeostasis and disease. Trends Immunol 2009;30:43-51